Vetstoria vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Veterinary Online Appointment Booking Platform
Real-time online appointment booking platform for veterinary practices; Dublin Ireland; raised $8M+; integrates with ezyVet, Provet Cloud, Cornerstone, and Avimark to synchronize 24/7 online bookings with clinic PIMS;
About
Vetstoria is a real-time online appointment booking platform built specifically for veterinary practices, enabling pet owners to book appointments online 24/7 through a clinic's website without phone calls, while giving veterinary teams full control over appointment types, availability, and booking rules. Founded in 2016 and headquartered in Dublin, Ireland, Vetstoria has raised approximately $8 million and grown to serve thousands of veterinary practices globally in Europe, the US, Australia, and Asia, integrating with leading practice management systems to synchronize appointments in real time.\n\nVetstoria's booking platform connects directly to a clinic's veterinary information management system — including ezyVet, Provet Cloud, Cornerstone, Avimark, and others — so bookings made online appear immediately in the practice schedule without staff intervention, and availability shown to clients accurately reflects real-time slot availability. Clinics control which appointment types are bookable online, can set deposit requirements for high-demand slots, and can restrict booking access to existing clients only. Analytics provide data on booking conversion rates, booking source (website, Google, social), and time-of-day patterns.\n\nVetstoria competes with PetDesk, Vetster, and general appointment booking platforms adapted from human healthcare in the veterinary booking space. Its deep PIMS integrations and purpose-built veterinary rules engine — which can handle species-specific booking logic, new patient workflows, and emergency appointment routing — differentiate it from generic online booking tools. The platform helps veterinary practices capture after-hours booking demand, reduce front-desk call volume, and improve the client experience for digitally-oriented pet owners.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.